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ABSTRACT
Introduction: Despite the fact that perianal
fistulas are associated with significant morbidity
and impaired quality of life, their prevalence in
Europe is unknown. The aim of this study was
to estimate the prevalence of perianal fistulas in
Europe, overall and according to etiology.
Methods: Two independent literature reviews
were performed using different search strategies
to maximize the identification of potentially
relevant studies. Data from relevant articles
were used to estimate the prevalence of perianal
fistulas in Europe. The robustness of the esti-
mate was evaluated using data from a large
population-based database from the UK.
Results: A total of 26 studies provided epi-
demiological data on perianal fistulas, of which
16 provided suitable data to estimate the
prevalence. Estimations using these data yielded
a total prevalence of 1.69 per 10,000 popula-
tion. Cryptoglandular infection and Crohn’s
disease (CD) were the predominant etiologies,
with prevalence rates at 0.86 and 0.76 per
10,000 population, respectively. Comparison of
prevalence data from the UK population-based
database with the European population resulted
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in a standardized prevalence estimate of all
perianal fistulas of 1.83 per 10,000 population,
confirming the robustness of the literature-
based estimate.
Conclusion: Although in terms of incidence
cryptoglandular fistulas were clearly predomi-
nant, the prevalence of fistulas in CD and
cryptoglandular infection appeared more bal-
anced. This is due to the longer duration and
higher frequency of relapses of fistulas in CD.
The estimated prevalence implies that perianal
fistulas meet the criteria to be considered as a
rare condition in Europe (prevalence less than 5
per 10,000 population).
Funding: This study was funded by Takeda
Pharmaceutical U.S.A., Inc. and TiGenix SAU.
Keywords: Anal fistula; Epidemiology; Europe;
Incidence; Prevalence
Key Summary Points
Why carry out this study?
Perianal fistulas are associated with
significant morbidity and impaired
quality of life. However, their prevalence
in Europe is unknown.
What was learned from the study?
This article describes two independent
literature reviews showing a prevalence of
perianal fistulas in Europe of 1.69 per
10,000 population.
Cryptoglandular infection and Crohn’s
disease were the predominant aetiologies,
with prevalence of 0.86 and 0.76 per
10,000 population, respectively.
Analyses of a large population-based
database from the UK confirmed the
robustness of this estimate.
The data indicate that perianal fistulas
meet the criterion to be considered a rare
condition in Europe (prevalence less than
5 per 10,000 population established by the
European Medicines Agency).
INTRODUCTION
Fistulas are abnormal connections between two
epithelialized surfaces [1, 2]. An external fistula
is defined as one that connects an internal
organ and the skin surface [3]. According to the
most widely accepted definition, an anal fistula
is an external fistula that creates an abnormal
connection between the anorectum and peri-
anal epithelium [4–7]. Anal fistulas are associ-
ated with significant clinical manifestations
(e.g., local pain, phlogosis, purulent drainage,
and incontinence) and impaired health-related
quality of life [6]. Although surgery of anal fis-
tulas is one of the most common operations
performed by colorectal surgeons and new
therapies for this condition make epidemiologic
data relevant for heathcare planning, the
prevalence of this condition remains largely
unknown.
Most anal fistulas are either of cryptoglan-
dular origin or secondary to Crohn’s disease
(CD), although a variety of other etiologies have
been identified, including infection, trauma,
cancer, and congenital malformation. Whereas
cryptoglandular anal fistulas are assumed to be
caused by an infection of the anal glands [6, 8],
those related to CD appear to be a consequence
of anorectal lesions produced by the transmural
inflammatory process [9, 10].
The aim of the present study was to estimate
the prevalence of anal fistulas in Europe overall
and by etiology.
METHODS
For this study, the most common definition of
anal fistula was used (abnormal connection
between the anorectum and perianal skin).
Other suppurating perianal/perirectal condi-
tions are beyond the scope of this work.
Literature Review
To optimize the probability of retrieving rele-
vant articles, two separate systematic literature
searches were conducted. The first was a tar-
geted search of the MEDLINE database,
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performed using a series of specific search terms
covering the different etiologies of anal fistulas.
The second employed more generic search
terms, and included studies indexed in MED-
LINE, Embase, and Cochrane databases. In this
case, search terms referred to anal fistulas, but
not to their specific etiologies. The full search
algorithms are available in Supplementary
Material Files 1 and 2.
The two searches, completed in December
2017, were conducted independently, and the
retrieved titles and abstracts were screened by
two independent reviewers. No restrictions were
placed on the type of study or publication
included, with selection based solely on the
relevance of data reported to the study ques-
tion. Eligible studies were those published in
English, reporting European population-based
epidemiologic data on anal fistulas, with an
appropriate case definition, from which preva-
lence could be estimated. Potentially relevant
articles were subjected to full text review and
those fulfilling the aforementioned selection
criteria were used to estimate the prevalence of
anal fistulas.
Bibliographies of the selected articles were
screened to identify any additional sources of
relevant data.
For etiologies in which only incident cases
were reported or could be derived, prevalence
was estimated from the reported incidence and
the median duration of the condition, based on
the following equation relating to both vari-
ables [11]:
Point prevalence ¼ incidence  duration of condition
For etiologies leading to fistulas of 1-year
duration or less, incidence was assumed to
represent a conservative estimate of prevalence.
The overall prevalence of CD-related anal
fistulas was calculated as the mean prevalence
of anal fistulas in the Crohn’s population,
obtained from population-based, cross-sectional
studies, multiplied by the weighted mean
prevalence of CD/10,000 population in Europe,
obtained from studies published over the last
10 years (2008–2017; Supplementary Material
File 3) [12–31]. The weighted mean prevalence
of Crohn’s disease was calculated on the basis of
the 2017 mid-year populations [32].
The literature review is based on previously
conducted studies and does not contain any
studies with human participants or animals
performed by any of the authors.
While the study was not captured in a data-
base, the PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) guide-
lines [33] were followed as closely as possible to
ensure reporting transparency. Given the nature
of the data collected, it was deemed inappro-
priate to attempt a meta-analysis of the extrac-
ted data, and this study is a systematic review of
the literature only.
Population-Based Database Analysis
To validate the estimates derived from the lit-
erature, the prevalence of anal fistulas among
patients in a population-based healthcare data-
base in the UK was compared with the European
population. This analysis employed The Health
Improvement Network (THIN) [34], a primary
care database containing electronic medical
records for more than 3 million active patients.
Relevant diagnostic and surgical codes were
used to identify cases of anal fistula (Supple-
mentary Material File 4). To account for the
longer duration of anal fistulas in CD compared
with non-CD etiologies, prevalence estimates
were calculated using an assumed duration of at
most 4 years for anal fistulas related to CD and
at most 12 months for etiologies other than CD,
following clinical judgement and published
data [35]. Anal fistulas in CD were defined as
having a CD diagnosis at any time before or up
to 4 years after the anal fistula diagnosis, as anal
fistulas may be the first manifestation of CD.
Prevalence was calculated on the basis of the
numbers of prevalent cases of anal fistulas and
active patients as of July 1 of each year.
To facilitate standardization to the UK and
European population reference sets, prevalence
estimates were stratified by age and sex. The
latest population reference sets for the UK
(2016) [36] and Europe (2013) [37] were then
used to extrapolate prevalence estimates to the
UK and European populations, respectively.
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The population-based database analysis was
reviewed and approved by the THIN Scientific
Review Committee (SRC 18THIN006). The
study conformed to the Helsinki Declaration of
1964, as revised in 2013, and Springer’s ethical
policy.
RESULTS
The two literature searches yielded totals of 596
and 356 publications, of which 26 and 6,
respectively, were found to provide epidemio-
logic data related to anal fistulas, with an over-
lap of six references. After full text review, 16
studies in total were found suitable to be used as
data sources to estimate the prevalence of anal
fistulas (Fig. 1, Table 1). Where recorded, the
included cohorts were predominantly male and
aged 30–50 years (Table 1) [38–53]. The ten
excluded studies and the corresponding reasons
for exclusion are listed in Supplementary
Material File 5.
Anal Fistulas of Cryptoglandular Origin
A single article provided data suitable to derive
the prevalence of anal cryptoglandular fistulas.
Sainio [38] estimated the incidence among the
residents of Helsinki, based on the number of
patients hospitalized for surgery related to anal
fistulas of cryptoglandular origin from 1969 to
1978. Although conducted in a hospital setting,
the study provided a population-based per-
spective, as surgical intervention is the primary
treatment modality in virtually all patients with
this type of anal fistula. The reported annual
incidence was 0.86/10,000 population. Given
the limited duration of the condition (on aver-
age up to 1 year according to clinical experi-
ence), the reported incidence represents an
acceptable estimate of the prevalence.
Crohn’s Disease-Related Anal Fistulas
The estimated prevalence of anal fistulas related
to CD was based on four studies (Table 2).
A Spanish group conducted a cross-sectional
study in 635 consecutive outpatients from 39
randomly selected clinics and hospitals [39]. It
reported perianal disease in 12.0% of patients
with CD. Based on evidence suggesting that
50% of patients with CD and perianal involve-
ment have perianal fistulas [54], the estimated
prevalence of anal fistulas in CD was 6.0%. Of
note, these data can be considered population-
based as the vast majority of patients with CD in
Spain are diagnosed and followed in secondary
and tertiary centers.
A second Spanish study evaluated the inci-
dence of perianal fistulas in 2391 patients with
CD treated in secondary and tertiary institu-
tions, and reported an annual incidence of 1.2%
[40]. On the basis of the median duration of
anal fistulas in patients with CD [35], the
annual incidence reported in the present study
was multiplied by a median duration of
3.6 years, resulting in an estimated prevalence
of 4.3% among the CD population.
In a Dutch population-based study evaluat-
ing anal fistulas in 1162 patients with CD,
Go¨ttgens et al. [41] reported an incidence of
8.3% during the first year following initial
diagnosis of CD and a cumulative incidence of
15.8% at 10 years after diagnosis. Analysis of the
data suggested that the cumulative incidence
during years 2–10 after the initial diagnosis of
CD (7.5%) was linear, yielding an annual inci-
dence of 0.83% over this period. To estimate
prevalence, annual incidence was derived from
the annual incidence estimates of 8.3% during
the first year after diagnosis and 0.83% during
years 2–10 applied to the mean incidence and
prevalence of CD (1.4/10,000 and 25.14/10,000
population, respectively; means of figures re-
cently reported in two Dutch studies) [22, 23].
The resulting annual incidence of anal fistulas
in patients with CD (0.31/10,000 population)
was multiplied by the median duration of the
condition (3.6 years), yielding an estimated
prevalence of 1.13/10,000 population. Consid-
ering the aforementioned prevalence of CD in
the Netherlands, it was concluded that the
prevalence of anal fistulas in the CD population
was 4.49%.
Finally, Georgiadou et al. [42] performed a
retrospective analysis of a German claims data-
base that included 13,346 patients with CD.
Among these patients, 451 had a concurrent
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diagnosis of perianal fistula, suggesting an
overall prevalence of 3.38%.
The mean prevalence of anal fistulas in CD
across the four studies was 4.55%. Extrapolation
to the European population using a weighted
mean prevalence of CD of 16.63/10,000 popu-
lation (Fig. 2) yielded an estimated prevalence
of CD-related anal fistulas of 0.76/10,000 pop-
ulation. Based on a median duration of
3.6 years, the estimated annual incidence of
CD-related anal fistulas was 0.21/10,000
population.
Trauma-Induced Anal Fistulas
Six studies provided data on the prevalence of
anal fistulas related to iatrogenic trauma, all of
which assessed the frequency of anal fistulas
Fig. 1 Study flow diagram corresponding to the a targeted literature search and b systematic literature search
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subsequent to hemorrhoidectomy (Table 3)
[43–48].
The weighted mean frequency of anal fistulas
reported as a complication of hemorrhoidec-
tomy in the studies included in this analysis was
0.69%. Based on an estimated annual frequency
of 4.5 hemorrhoidectomies/10,000 population
derived from studies in Germany and England
[55, 56], the estimated incidence of post-hem-
orrhoidectomy anal fistulas in Europe was 0.31/
10,000 population. Given the short duration of
the condition, this incidence represents a con-
servative estimate of the prevalence of anal fis-
tulas following hemorrhoidectomy.
Anal Fistulas Related to Other Etiologies
Five studies were identified with suitable data to
facilitate estimation of the prevalence of anal
fistulas related to other etiologies, including
infection, cancer, and congenital malformation
[49–53]. Table 4 summarizes the estimated
prevalence of these etiologies of anal fistulas
based on the studies included in this analysis.
Three studies reporting suitable data on anal
fistulas related to infection were identified,
including two reports on anal fistulas in
patients with tuberculosis and one case series in
patients with lymphogranuloma venereum
[49–51]. According to the most recent estimate
from the European Centre for Disease
Fig. 1 continued
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Table 1 Studies used as source of data in the analysis of the prevalence of anal fistulas in Europe
Etiology Study Region Design Number
of
patients
included
Male
(%)
Average
age
(years)
Estimation made from
the reported data
Cryptoglandular Sainio 1984
[38]
Finland Retrospective
analysis
458 63 38a Prevalence of
cryptoglandular anal
fistula
Crohn’s disease SEESG-CD
1999 [39]
Spain Cross-sectional
observation
study
635 48 33 Prevalence of Crohn’s-
related anal fistula
Chaparro
et al. 2011
[40]
Spain Population-
based cohort
study
2391 55 41b Prevalence of Crohn’s-
related anal fistula
Go¨ttgens
et al. 2017
[41]
Netherlands Population-
based cohort
study
1162 37 38c Prevalence of Crohn’s-
related anal fistula
Georgiadou
et al. 2019
[42]
Germany Cross-sectional
claims
database
analysis
13,346 NR NR Prevalence of Crohn’s-
related anal fistula
Trauma Sielezneff
et al. 1997
[43]
France Retrospective
cohort study
1134 71 48 Prevalence of trauma-
related anal fistula
(iatrogenic)
Rosa et al.
2005 [44]
Italy Retrospective
cohort study
374 60 42b Prevalence of trauma-
related anal fistula
(iatrogenic)
Sultan et al.
2010 [45]
France Prospective
study
150 81 50 Prevalence of trauma-
related anal fistula
(iatrogenic)
Bouchard
et al. 2013
[46]
France Prospective
study
633 43 48b Prevalence of trauma-
related anal fistula
(iatrogenic)
Bjelanovic
et al. 2016
[47]
Spain Prospective
observational
study
402 67 46 Prevalence of trauma-
related anal fistula
(iatrogenic)
Milito et al.
2017 [48]
Italy Retrospective
cohort study
1000 NR 19–80d Prevalence of trauma-
related anal fistula
(iatrogenic)
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Prevention and Control, the prevalence of
tuberculosis in Europe is 1.65/10,000 popula-
tion [57]. Alvarez Conde et al. [50] reported that
0.7% of patients with tuberculosis have perianal
involvement, which corresponds to a preva-
lence of 0.012/10,000 population in Europe.
Among these patients, anal fistulas were the
most common presentation, occurring in
80–91% [51], suggesting a prevalence of tuber-
culosis-related anal fistulas of 0.009–0.011 per
10,000 population, with a median of 0.1/
10,000. In a case series of 27 patients with
lymphogranuloma venereum, Scieux et al. [49]
observed two cases of anal fistulas (7.4%). Based
on the reported prevalence of 0.08 cases of
lymphogranuloma venereum/10,000 in Europe
[58], the estimated prevalence of anal fistulas
related to lymphogranuloma venereum was
0.006/10,000 population. Combined with the
estimated prevalence of tuberculosis-related fis-
tulas, these data indicate a prevalence of anal
fistulas related to infection of 0.016/10,000
population.
A single article reporting data on anal fistulas
in patients with anal adenocarcinoma met the
criteria for inclusion. In a case series of 21
patients with anal adenocarcinoma, Jensen
et al. [52] reported that anal fistulas occurred in
23.8%. Assuming a prevalence of 0.11 cases of
anal adenocarcinoma/10,000 population in
Table 1 continued
Etiology Study Region Design Number
of
patients
included
Male
(%)
Average
age
(years)
Estimation made from
the reported data
Systemic
infection
Scieux et al.
1989 [49]
France Case series 27 100 17–73d Prevalence of infection-
related anal fistula
(lymphogranuloma
venereum)
Alvarez
Conde
et al. 1992
[50]
Spain Cases report
and review
NA NA NA Prevalence of infection-
related anal fistula
(tuberculosis)
Gupta et al.
2005 [51]
NR Review NA NA NA Prevalence of infection-
related anal fistula
(tuberculosis)
Cancer Jensen et al.
1988 [52]
Denmark Case series 21 38 70b Prevalence of
adenocarcinoma-
related anal fistula
Congenital Cuschieri
2001 [53]
Europe Epidemiologic
registry survey
4.6 M NR Newborns Prevalence of
congenital anal fistula
M million, NA not applicable, NR not reported, SEESG-CD Spanish Epidemiological and Economic Study Group on
Crohn’s disease
a Only reported for nonspecific anal fistula (414 patients)
b Median age
c Mean age at time of CD diagnosis
d Age range only reported
3510 Adv Ther (2019) 36:3503–3518
Europe [59], this corresponds to a prevalence of
anal adenocarcinoma-related fistulas of 0.026/
10,000 population. Considering that a propor-
tion of anal adenocarcinoma-related fistulas
occur in patients with CD, the prevalence of
these fistulas in the non-CD population has
been calculated by subtracting the mean esti-
mated prevalence of fistula-related anal cancers
in CD in Europe based on published data
(0.006/10,000 population) [60–62], resulting in
an estimated prevalence of 0.02/10,000
population.
The literature searches retrieved one suit-
able article on congenital anal fistulas. In a 2001
European epidemiologic study, Cuschieri et al.
[53] reported a prevalence of 1.04 congenital
anal fistulas/10,000 live births. Extrapolation of
the estimate to the European Union population
using the most recent data for the annual
number of live births (5.1 million) [63] and the
total population (508.5 million) [63] resulted in
an estimated prevalence of 0.01/10,000
population.
Overall Prevalence of Anal Fistulas
in Europe
The overall prevalence of anal fistulas in Europe,
estimated as the sum of the estimated
prevalence for all etiologies, was 1.69/10,000
population (Table 5). CD and cryptoglandular
infection were the predominant etiologies,
accounting for more than 95% of all cases. In
comparison, the overall incidence of anal fistu-
las in Europe was 1.15/10,000 population.
Population-Based Database Analysis
The results of the population-based database
analysis are summarized in Table 6. Comparison
of data from the UK THIN database with the
European population yielded a standardized
prevalence of 1.83 anal fistulas/10,000 popula-
tion (95% confidence interval 1.68–1.98) in
2017, with a range of 1.83–2.36/10,000 popu-
lation during the 4-year study period. The close
agreement between the estimates derived from
the THIN database and the systematic literature
reviews confirms the robustness of the litera-
ture-based estimate.
DISCUSSION
The present study represents the first systematic
literature reviews and corroborative analysis of a
large, population-based database to ascertain
the prevalence of anal fistulas in Europe. The
Table 2 Prevalence rates of anal fistulas among patients with Crohn’s disease, derived from European studies
Study Design Cohort source Number of
patients
included
Prevalence
(%)
SEESG-CD
1999 [39]
Cross-sectional
observation study
39 hospitals throughout Spain 635 6.0
Chaparro et al.
2011 [40]
Population-based
cohort study
11 hospitals in Madrid 2391 4.32
Go¨ttgens et al.
2017 [41]
Population-based
cohort study
Population-based IBD cohort in the
Netherlands (IBD South Limburg registry)
1162 4.49
Georgiadou
et al. 2019
[42]
Cross-sectional claims
database analysis
Claims data from several German company
health insurance funds
13,346 3.38
Totala 4.55
IBD inflammatory bowel disease, SEESG-CD Spanish Epidemiological and Economic Study Group on Crohn’s disease
a Weighted average
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findings suggest that the prevalence of anal fis-
tulas is 1.69/10,000 population, with an annual
incidence of 1.15/10,000 population. According
to the threshold definition of 5/10,000 popula-
tion established by the European Medicines
Agency, the estimated prevalence of anal fistu-
las meets the criteria for a rare condition [64].
A substantial majority of prevalent cases of
anal fistulas were either of cryptoglandular ori-
gin or secondary to CD (more than 95%); a
variety of etiologies, including infection,
trauma, cancer, and congenital malformation,
account for the remaining 5%. While anal fis-
tulas have occasionally been reported in
patients with certain infections, diabetes,
ulcerative colitis, and diverticulitis, such cases
are extremely rare. In terms of incidence, cryp-
toglandular fistulas were clearly predominant
compared with CD-related fistulas (75% vs
18%), whereas prevalence rates were relatively
balanced (51% vs 45%). Such differences were
driven by the longer duration and high-level
relapse of anal fistulas in CD.
The strengths of the present study include
the performance of two separate literature
reviews by independent reviewers and use of a
large population-based database as a validation
dataset. Population-based data sources are con-
sidered the gold standard for epidemiologic
analyses. In the present analysis, prevalence
estimates from population-based data sources
were adjusted to account for differences in the
duration of anal fistulas according to etiology,
bFig. 2 Reported prevalence of Crohn’s disease in Europe
by country published over the last 10 years (2008–2017).
Rates are per 10,000 population
Table 3 Prevalence rates of anal fistulas among patients undergoing hemorrhoidectomy, derived from European studies
Study Design Cohort source Number of patients
included
Prevalence
(%)
Sielezneff et al.
1997 [43]
Retrospective cohort
study
A French hospital (1975–1990) 1134 1.2
Rosa et al. 2005
[44]
Retrospective cohort
study
A UK hospital (1983–2002) 374 0.5
Sultan et al. 2010
[45]
Prospective study A French hospital (2001–2006) 150 0.67
Bouchard et al.
2013 [46]
Prospective study Multiple hospitals across France
(2007–2008)
633 0.16
Bjelanovic et al.
2016 [47]
Prospective
observational study
A surgical center in Spain
(2010–2014)
402 1.2
Milito et al. 2017
[48]
Retrospective cohort
study
An Italian hospital (2001–2014) 1000 0.3
Totala 0.69
a Weighted average
Table 4 Estimated prevalence rates of anal fistulas related
to etiologies other than Crohn’s disease and cryptoglan-
dular infection
Etiology Prevalence (per 10,000 population)
Infection 0.016
Trauma 0.031
Cancer 0.02
Congenital 0.01
Total 0.078
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and results from the database were stratified by
age and sex to facilitate extrapolation to the
European population. Importantly, the close
agreement between the estimates derived from
the literature reviews and population-based
database analysis provided compelling corrob-
orative evidence to support the robustness of
the findings.
The present findings should be interpreted in
the context of certain limitations, including the
limited number of studies with suitable data to
support estimation of the prevalence of certain
etiologies of anal fistulas, and the low number
of patients included in some studies. Given the
scarcity of epidemiological data, the authors
assumed that the identified papers from the first
literature search would be significantly
heterogeneous, not only in terms of study
design and reported epidemiology outcomes
but also in terms of quality. As such, a formal
comparative assessment of quality/bias was not
conducted. For the second literature search, the
risk of bias in the identified studies was assessed
and, as expected, wide heterogeneity (percent-
ages of items at high risk of bias in the different
studies ranged from 0 to 60%) was reported. As
such, heterogeneity in the risk of bias between
studies is a limitation of this study. Addition-
ally, it should be considered that the average
duration of anal fistulas in CD used to estimate
the prevalence of this fistula etiology comes
from a study conducted in the pre-biologic era,
and thus it cannot be ruled out that the average
duration has changed. Finally, the analysis of
Table 5 Estimated prevalence and incidence of anal fistulas in Europe
Etiology Prevalence (per 10,000
population)
Proportion of
prevalent cases (%)
Incidence (per 10,000
population)
Proportion of
incident cases (%)
Cryptoglandular 0.86 50.8 0.86 74.9
Crohn’s disease 0.76 44.6 0.21 18.3
Othera 0.078 4.6 0.078 6.8
Total 1.69 100.0 1.15 100.0
a Includes infections, trauma, anal adenocarcinoma, and congenital malformation
Table 6 Prevalence of anal fistulas based on analysis of data from the UK THIN database
2017 2016 2015 2014
Active patients, n 3,172,922 3,569,535 4,219,577 4,875,428
Patients with anal fistula, na 579 688 938 1143
Total per 10,000 population 1.82 1.93 2.22 2.34
UK standardized estimate per 10,000 population
(95% CI)b
1.80
(1.65–1.94)
1.89
(1.75–2.03)
2.19
(2.05–2.33)
2.31
(2.18–2.44)
EU standardized estimate per 10,000 population (95%
CI)c
1.83
(1.68–1.98)
1.94
(1.79–2.08)
2.23
(2.08–2.37)
2.36
(2.22–2.50)
Mid-year point prevalence calculated on the basis on the number of prevalent cases of anal fistula as of July 1 each year and
the number of active patients on July 1 of the corresponding year
CI confidence interval
a Includes anal fistulas within the previous 12 months in patients without Crohn’s disease and anal fistulas within the
previous 4 years in patients with Crohn’s disease
b Stratified by age and sex, and standardized to the UK population based on 2016 census data [33]
c Stratified by age and sex, and standardized to the EU populations based on 2013 population estimates [34]
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data from the population-based primary care
database was subject to potential bias due to
misclassification or underreporting of diagnoses
and procedures.
CONCLUSIONS
It was estimated from the published literature
that the prevalence of anal fistulas in Europe is
1.69/10,000 population. The robustness of this
estimate was confirmed by analysis of data from
a population-based database (1.83/10,000
population).
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